MCID: HPT022
MIFTS: 55

Hepatoblastoma

Categories: Rare diseases, Liver diseases, Cancer diseases

Aliases & Classifications for Hepatoblastoma

MalaCards integrated aliases for Hepatoblastoma:

Name: Hepatoblastoma 12 72 49 28 51 41 14 69
Hbl 12

Classifications:



External Ids:

Disease Ontology 12 DOID:687
ICD10 32 C22.2
MeSH 41 D018197
NCIt 46 C3728
SNOMED-CT 64 109843000 45024009
UMLS 69 C0206624

Summaries for Hepatoblastoma

NIH Rare Diseases : 49 Hepatoblastoma is a rare malignant (cancerous) tumor of the liver that usually occurs in the first 3 years of life. In early stages of the condition, there may be no concerning signs or symptoms. As the tumor gets larger, affected children may experience a painful, abdominal lump; swelling of the abdomen; unexplained weight loss; loss of appetite; and/or nausea and vomiting. The exact underlying cause of hepatoblastoma is poorly understood. Risk factors for the tumor include prematurity with a very low birth weight, early exposure to hepatitis B infection, biliary atresia, and several different genetic conditions (i.e. Beckwith-Wiedemann syndrome, familial adenomatous polyposis, Aicardi syndrome, Glycogen storage disease, and Simpson-Golabi-Behmel syndrome). Treatment varies based on the severity of the condition but may include a combination of surgery, watchful waiting, chemotherapy, and/or radiation therapy. Last updated: 1/20/2016

MalaCards based summary : Hepatoblastoma, also known as hbl, is related to beckwith-wiedemann syndrome and simpson-golabi-behmel syndrome, and has symptoms including icterus An important gene associated with Hepatoblastoma is APC (APC, WNT Signaling Pathway Regulator), and among its related pathways/superpathways are Endometrial cancer and PI3K-Akt signaling pathway. The drugs Lenograstim and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include liver, fetal liver and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 Hepatoblastoma is an uncommon malignant liver cancer occurring in infants and children and composed of... more...

Related Diseases for Hepatoblastoma

Diseases related to Hepatoblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
# Related Disease Score Top Affiliating Genes
1 beckwith-wiedemann syndrome 31.3 AFP CDKN1C GPC3 H19 IGF2 SLC22A18
2 simpson-golabi-behmel syndrome 30.3 CTNNB1 GPC3 IGF2
3 hemihyperplasia, isolated 30.1 CDKN1C H19 IGF2
4 familial adenomatous polyposis 1 30.1 APC CTNNB1
5 hepatocellular carcinoma 29.7 ABCB1 AFP APC BCL2L1 BIRC5 CASP3
6 wilms tumor 5 29.6 CDKN1C CTNNB1 GPC3 H19 IGF2
7 childhood hepatocellular carcinoma 29.5 CTNNB1 MET
8 adenoma 29.4 APC CTNNB1 KRT7 PLAG1
9 hepatic adenomas, familial 29.2 AFP APC CTNNB1 GPC3 HNF1A
10 cholangiocarcinoma 28.4 AFP GPC3 HGF KRT7 MET
11 mixed hepatoblastoma 12.1
12 macrotrabecular hepatoblastoma 11.9
13 hypobetalipoproteinemia, familial, 2 11.2
14 chylomicron retention disease 10.9
15 silver-russell syndrome due to an imprinting defect of 11p15 10.6 H19 IGF2
16 silver-russell syndrome due to 11p15 microduplication 10.6 H19 IGF2
17 beckwith-wiedemann syndrome due to imprinting defect of 11p15 10.6 H19 IGF2
18 desmoid disease, hereditary 10.6 APC CTNNB1
19 testicular malignant germ cell cancer 10.5 AFP GPC3
20 nutmeg liver 10.5 BCL2L1 CASP3
21 intrahepatic bile duct adenoma 10.4 AFP KRT7
22 lung acinar adenocarcinoma 10.4 CTNNB1 KRT7
23 bladder benign neoplasm 10.3 IGF2 KRT7
24 ovarian embryonal carcinoma 10.3 AFP GPC3
25 silver-russell syndrome due to a point mutation 10.3 CDKN1C IGF2
26 fetal macrosomia 10.3 APOA1 H19 IGF2
27 hepatitis 10.3
28 gastrointestinal system benign neoplasm 10.3 CTNNB1 KRT7 PLAG1
29 large intestine adenocarcinoma 10.3 CTNNB1 KRT7
30 seminal vesicle tumor 10.3 AFP GPC3 KRT7
31 rhabdomyosarcoma, embryonal, 1 10.3 ABCB1 SLC22A18
32 testicular yolk sac tumor 10.2 AFP APOA1 GPC3
33 ovarian endodermal sinus tumor 10.2 AFP GPC3 KRT7
34 organ system benign neoplasm 10.2 CTNNB1 KRT7 PLAG1
35 ovarian primitive germ cell tumor 10.2 AFP GPC3 KRT7
36 bile duct adenocarcinoma 10.2 AFP GPC3 KRT7
37 cell type benign neoplasm 10.2 CTNNB1 KRT7 PLAG1
38 ovarian germ cell cancer 10.2 AFP KRT7
39 vulvar intraepithelial neoplasia 10.2 BIRC5 KRT7
40 female reproductive endometrioid cancer 10.2 CTNNB1 KRT7
41 colon adenocarcinoma 10.2 ABCB1 CASP3 CTNNB1
42 acinar cell carcinoma 10.1 AFP APC CTNNB1 KRT7
43 umbilical hernia 10.1 CDKN1C H19 IGF2
44 alpha-fetoprotein deficiency 10.1
45 intrahepatic cholangiocarcinoma 10.1 AFP CTNNB1 GPC3 KRT7
46 papillary craniopharyngioma 10.1 CTNNB1 KRT7
47 cell type cancer 10.1 AFP CASP3 CTNNB1 KRT7
48 familial adenomatous polyposis 10.1
49 ovarian cancer 1 10.1 BCL2L1 CASP3 CTNNB1 KRT7
50 neuroblastoma 10.0

Graphical network of the top 20 diseases related to Hepatoblastoma:



Diseases related to Hepatoblastoma

Symptoms & Phenotypes for Hepatoblastoma

UMLS symptoms related to Hepatoblastoma:


icterus

GenomeRNAi Phenotypes related to Hepatoblastoma according to GeneCards Suite gene sharing:

25 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.96 CTNNB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.96 CTNNB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.96 AFP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.96 IGF2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.96 AFP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.96 IGF2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.96 APC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.96 KRT7
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.96 IGF2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.96 IGF2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.96 APC CTNNB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.96 APC KRT7 AFP
13 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.96 CTNNB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.96 APC
15 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.96 AFP APC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.96 CTNNB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.96 APC CTNNB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.96 IGF2 AFP
19 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.96 CTNNB1 IGF2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.96 CTNNB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.96 APC CTNNB1 KRT7 IGF2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.96 CTNNB1 IGF2
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.83 HNF1A
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 9.83 HNF1A
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 9.83 HNF1A
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.83 HNF1A
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 9.83 HNF1A
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-38 9.83 HNF1A
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.83 KRT7
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.83 KRT7
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.83 KRT7 APC CDKN1C HNF1A
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.83 HNF1A
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.83 CDKN1C KRT7

MGI Mouse Phenotypes related to Hepatoblastoma:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.34 HGF HNF1A IGF2 KRT7 MET PPARA
2 cardiovascular system MP:0005385 10.28 MET PPARA ABCB1 APC APOA1 CASP3
3 homeostasis/metabolism MP:0005376 10.28 GPC3 HNF1A IGF2 KRT7 MET PPARA
4 endocrine/exocrine gland MP:0005379 10.27 APOA1 BCL2L1 BIRC5 CASP3 CDO1 CTNNB1
5 growth/size/body region MP:0005378 10.25 ABCB1 APC BCL2L1 CASP3 CDO1 CTNNB1
6 digestive/alimentary MP:0005381 10.1 CTNNB1 GPC3 HNF1A IGF2 MET ABCB1
7 mortality/aging MP:0010768 10.1 PPARA ABCB1 AFP APC BCL2L1 BIRC5
8 embryo MP:0005380 10.08 APC BIRC5 CTNNB1 GPC3 HGF IGF2
9 craniofacial MP:0005382 10.05 APC CASP3 CDO1 CTNNB1 GPC3 IGF2
10 integument MP:0010771 10.02 APC APOA1 BCL2L1 CASP3 CTNNB1 GPC3
11 liver/biliary system MP:0005370 10.02 ABCB1 AFP APC APOA1 CTNNB1 HGF
12 no phenotypic analysis MP:0003012 9.76 ABCB1 APC CASP3 CTNNB1 HGF HNF1A
13 renal/urinary system MP:0005367 9.56 APC CASP3 CTNNB1 GPC3 HNF1A IGF2
14 reproductive system MP:0005389 9.36 ABCB1 AFP APC BCL2L1 CASP3 CDO1

Drugs & Therapeutics for Hepatoblastoma

Drugs for Hepatoblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 1 135968-09-1
2
Nicotine Approved Phase 4 54-11-5 89594 942
3 Adjuvants, Immunologic Phase 4,Phase 1
4
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
5
Etoposide Approved Phase 3,Phase 1,Phase 2 33419-42-0 36462
6
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
7
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
9
Vincristine Approved, Investigational Phase 3,Phase 1 2068-78-2, 57-22-7 5978
10
Oxaliplatin Approved, Investigational Phase 3,Phase 2 61825-94-3 43805 6857599 5310940 9887054
11
Amifostine Approved, Investigational Phase 3,Phase 1 20537-88-6 2141
12
Fluorouracil Approved Phase 3 51-21-8 3385
13
Gemcitabine Approved Phase 3 95058-81-4 60750
14
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
15
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
16
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
17
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
18
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
19
Cyproheptadine Approved Phase 3 129-03-3 2913
20
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
21
Doxil Approved June 1999 Phase 3,Phase 2 31703
22 sodium thiosulfate Phase 3
23 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
24 Chelating Agents Phase 3
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
26 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
27 Antidotes Phase 3
28 Anti-Infective Agents Phase 3,Phase 2,Phase 1
29 Etoposide phosphate Phase 3,Phase 1,Phase 2
30 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
31 Protective Agents Phase 3,Phase 1
32 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
33 Liver Extracts Phase 3,Phase 2,Phase 1
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
35 Antioxidants Phase 3
36 Antitubercular Agents Phase 3
37 Antimetabolites Phase 3,Phase 1
38 Antimetabolites, Antineoplastic Phase 3
39 Antimitotic Agents Phase 3,Phase 1
40 Radiation-Protective Agents Phase 3,Phase 1
41 Hematinics Phase 3
42 Antifungal Agents Phase 3,Phase 2,Phase 1
43 Protein Kinase Inhibitors Phase 3
44 Antiviral Agents Phase 3
45
Histamine Phosphate Phase 3 51-74-1 65513
46
Serotonin Phase 3 50-67-9 5202
47 Serotonin Agents Phase 3
48 Serotonin Antagonists Phase 3
49 Gastrointestinal Agents Phase 3
50 Neurotransmitter Agents Phase 3

Interventional clinical trials:

(show all 44)

# Name Status NCT ID Phase Drugs
1 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
2 Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, Stage II, or Stage III Childhood Liver Cancer Unknown status NCT00652132 Phase 3 cisplatin;sodium thiosulfate
3 Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer Completed NCT00003994 Phase 3 cisplatin;vincristine sulfate;fluorouracil;amifostine trihydrate;carboplatin
4 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
5 Chemotherapy in Treating Children With Liver Cancer Completed NCT00003912 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride
6 Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Recruiting NCT00980460 Phase 3 Cisplatin;Doxorubicin Hydrochloride;Fluorouracil;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate
7 Paediatric Hepatic International Tumour Trial Recruiting NCT03017326 Phase 3 Cisplatin;Doxorubicin;Carboplatin;5Fluorouracil;Vincristine;Etoposide;Irinotecan;Gemcitabine;Oxaliplatin;Sorafenib
8 Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
9 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
10 Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma Unknown status NCT00287976 Phase 2 irinotecan hydrochloride
11 Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma Unknown status NCT00077389 Phase 2 carboplatin;cisplatin;doxorubicin hydrochloride
12 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
13 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed NCT01125800 Phase 1, Phase 2 LDE225
14 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib
15 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
16 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
17 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
18 Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Recruiting NCT01956669 Phase 2 Pazopanib GW786034
19 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate
20 Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations Recruiting NCT03220035 Phase 2 Vemurafenib
21 Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes Recruiting NCT03233204 Phase 2 Olaparib
22 Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib
23 Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
24 Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations Recruiting NCT03213665 Phase 2 Tazemetostat
25 Pediatric MATCH: Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations Recruiting NCT03210714 Phase 2 Erdafitinib
26 Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Vemurafenib
27 A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors Recruiting NCT01804634 Phase 2 Cyclophosphamide;Fludarabine;Melphalan;Sirolimus
28 Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Withdrawn NCT02011126 Phase 2 imetelstat sodium
29 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Unknown status NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
30 Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Recruiting NCT02390843 Phase 1 Simvastatin;Cyclophosphamide;Topotecan;Myeloid growth factor
31 Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting NCT01331135 Phase 1 sirolimus
32 A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy Active, not recruiting NCT02085148 Phase 1 Regorafenib (BAY73-4506);Vincristine (Cellcristin®);Irinotecan (Irinotecan Cell pharm®)
33 Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Terminated NCT00003926 Phase 1 amifostine trihydrate;busulfan;filgrastim;melphalan;thiotepa
34 MT2004-30: Tomotherapy for Solid Tumors Terminated NCT00623077 Phase 1 busulfan;etoposide;ifosfamide;melphalan;thiotepa;Mesna
35 Cancer and Hearing Loss Related in Children Unknown status NCT02425397
36 Biomarkers in Tissue Samples From Young Patients With Liver Cancer Completed NCT01336881
37 Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer Completed NCT01353300
38 Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Completed NCT00002485
39 Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience Recruiting NCT02557750
40 Understanding Communication in Healthcare to Achieve Trust (U-CHAT) Recruiting NCT02846038
41 Auto Transplant for High Risk or Relapsed Solid or CNS Tumors Recruiting NCT01505569 Ifosfamide;Etoposide;Mesna;Busulfan;Melphalan;Thiotepa;Carboplatin;Paclitaxel
42 Collecting and Storing Tissue From Young Patients With Cancer Recruiting NCT00898755
43 Hepatoblastoma Biology Study and Tissue Bank Withdrawn NCT00228683
44 Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors Withdrawn NCT00624962

Search NIH Clinical Center for Hepatoblastoma

Cochrane evidence based reviews: hepatoblastoma

Genetic Tests for Hepatoblastoma

Genetic tests related to Hepatoblastoma:

# Genetic test Affiliating Genes
1 Hepatoblastoma 28

Anatomical Context for Hepatoblastoma

MalaCards organs/tissues related to Hepatoblastoma:

38
Liver, Fetal Liver, Testes, Myeloid, Lung, Kidney, Brain

Publications for Hepatoblastoma

Articles related to Hepatoblastoma:

(show top 50) (show all 841)
# Title Authors Year
1
Pediatric patient with end-stage kidney disease secondary to Eagle-Barrett syndrome and metastatic unresectable hepatoblastoma treated successfully with chemotherapy and liver-kidney transplant. ( 29356335 )
2018
2
A novel tissue-based A9-catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among children with hepatoblastoma tumors. ( 29446530 )
2018
3
MiR-492 regulates metastatic properties of hepatoblastoma via CD44. ( 29314711 )
2018
4
Pediatric hepatoblastoma and hepatocellular carcinoma: lessons learned in the last decade. ( 29383417 )
2018
5
Hepatoblastoma: current understanding, recent advances, and controversies. ( 29375822 )
2018
6
Oridonin increases anticancer effects of lentinan in HepG2 human hepatoblastoma cells. ( 29434900 )
2018
7
Prognostic and therapeutic factors influencing the clinical outcome of hepatoblastoma after liver transplantation: A single-institute experience. ( 29341393 )
2018
8
Hepatoblastoma in a Child With Early-onset Cirrhosis. ( 29420370 )
2018
9
Expression Profiling Identifies Circular RNA Signature in Hepatoblastoma. ( 29414822 )
2018
10
Two Cases of Hepatoblastoma in Young Adults. ( 29412770 )
2018
11
20(S)-Protopanaxadiol induces apoptosis in human hepatoblastoma HepG2 cells by downregulating the protein kinase B signaling pathway. ( 29434714 )
2018
12
Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma. ( 28674120 )
2017
13
A Challenging Case of Hepatoblastoma Concomitant with Autosomal Recessive Polycystic Kidney Disease and Caroli Syndrome-Review of the Literature. ( 28638817 )
2017
14
Split liver transplantation for retroperitoneal immature teratoma masquerading as hepatoblastoma. ( 28714114 )
2017
15
Surgical treatment of childhood hepatoblastoma in the Netherlands (1990-2013). ( 27730288 )
2017
16
Genomic profiles of a hepatoblastoma from a patient with Beckwith-Wiedemann syndrome with uniparental disomy on chromosome 11p15 and germline mutation of APC and PALB2. ( 29190888 )
2017
17
Hepatoblastoma in an extremely low birth-weight infant with Beckwith-Wiedemann syndrome. ( 29203194 )
2017
18
Complete remission of refractory hepatoblastoma after liver transplantation in a child with sorafenib monotherapy: A new hope? ( 28696063 )
2017
19
Fractures in children with newly diagnosed hepatoblastoma. ( 29222581 )
2017
20
Ante situm liver resection with inferior vena cava replacement under hypothermic cardiopolmunary bypass for hepatoblastoma: Report of a case and review of the literature. ( 28651228 )
2017
21
MicroRNA therapy inhibits hepatoblastoma growth<i>in vivo</i>by targeting I^-catenin and Wnt signaling. ( 29404451 )
2017
22
A Novel Cell Line Based Orthotopic Xenograft Mouse Model That Recapitulates Human Hepatoblastoma. ( 29259231 )
2017
23
Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma. ( 28923827 )
2017
24
The role of pulmonary metastasectomy for hepatoblastoma in children with metastasis at diagnosis: Results from the JPLT-2 study. ( 28927977 )
2017
25
Recurrent Scapular Metastasis From Hepatoblastoma Shown on FDG PET/CT and F-DOPA PET/CT. ( 28806258 )
2017
26
Cure of Hepatoblastoma Through Transcatheter Arterial Chemoembolization. ( 29226184 )
2017
27
Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma. ( 28851352 )
2017
28
Fatal Central Nervous System Post-Transplant Lymphoproliferative Disease in a Patient Who Underwent Liver Transplantation for Hepatoblastoma. ( 28837514 )
2017
29
Hepatoblastoma in children aged less than six months at diagnosis: A report from the SIOPEL group. ( 28921839 )
2017
30
Fine needle aspiration in the diagnosis and classification of hepatoblastoma: Analysis of 21 New Cases. ( 27933740 )
2017
31
Molecular classification of hepatoblastoma and prognostic value of the HB 16-gene signature. ( 28510309 )
2017
32
Hepatoblastoma and Wolf-Hirschhorn syndrome: Coincidence or a new feature of a rare disease? ( 28786167 )
2017
33
Multimodality Treatment Outcome of Hepatoblastoma in a Resource Limited Country. ( 28588161 )
2017
34
Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group. ( 28892430 )
2017
35
Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. ( 27775819 )
2017
36
Multidisciplinary management of hepatoblastoma in children: Experience from a developing country. ( 27781375 )
2017
37
Hepatoblastoma: Transplant Versus Resection Experience in a Latin American Transplant Center. ( 28620649 )
2017
38
CXCL5 as an autocrine or paracrine cytokine is associated with proliferation and migration of hepatoblastoma HepG2 cells. ( 29344240 )
2017
39
Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. ( 27884679 )
2017
40
A systematic surgical approach to hepatoblastoma with intracardiac extension. ( 28457172 )
2017
41
Identification of differentially expressed genes, lncRNAs and miRNAs which are associated with tumor malignant phenotypes in hepatoblastoma patients. ( 29228631 )
2017
42
Downregulation of transcription factor GATA4 sensitizes human hepatoblastoma cells to doxorubicin-induced apoptosis. ( 28349834 )
2017
43
Hepatoblastoma: A success report using a combination therapy with preoperative arterial embolization. ( 28473171 )
2017
44
A common global risk stratification system for hepatoblastoma. ( 27884678 )
2017
45
Extreme hepatic resections for the treatment of advanced hepatoblastoma: Are planned close margins an acceptable approach? ( 28921939 )
2017
46
Circulating D-dimer level correlates with disease characteristics in hepatoblastoma patients. ( 29381980 )
2017
47
Exosomal miR-34s panel as potential novel diagnostic and prognostic biomarker in patients with hepatoblastoma. ( 28277300 )
2017
48
Serum alpha-fetoprotein screening for hepatoblastoma in Beckwith-Wiedemann syndrome. ( 28211991 )
2017
49
Hepatoblastoma in an 11-year-old: Case report and a review of the literature. ( 28079820 )
2017
50
Germline APC mutations in hepatoblastoma. ( 29251405 )
2017

Variations for Hepatoblastoma

ClinVar genetic disease variations for Hepatoblastoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
2 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
3 APC NM_000038.5(APC): c.4183A> T (p.Ser1395Cys) single nucleotide variant Pathogenic rs137854578 GRCh37 Chromosome 5, 112175474: 112175474

Copy number variations for Hepatoblastoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 48501 11 1 52900000 Methylation H19 Hepatoblastoma
2 48504 11 1 52900000 Methylation IGF2 Hepatoblastoma

Expression for Hepatoblastoma

Search GEO for disease gene expression data for Hepatoblastoma.

Pathways for Hepatoblastoma

Pathways related to Hepatoblastoma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.9 APC BCL2L1 BIRC5 CASP3 CTNNB1 HGF
2
Show member pathways
12.77 APC BCL2L1 CASP3 CTNNB1 HGF IGF2
3
Show member pathways
12.61 BCL2L1 CTNNB1 HGF IGF2 MET
4
Show member pathways
12.56 APC BCL2L1 CASP3 CTNNB1 HGF MET
5
Show member pathways
12.47 ABCB1 APC BCL2L1 CTNNB1 HGF IGF2
6
Show member pathways
12.33 BCL2L1 CASP3 CTNNB1 MET
7 12.32 APC BIRC5 CTNNB1 HNF1A
8
Show member pathways
12.27 BCL2L1 BIRC5 IGF2 MET
9 12.04 AFP APC BIRC5 CTNNB1
10 11.98 APC BCL2L1 CASP3 CTNNB1
11 11.98 APC BCL2L1 BIRC5 CASP3 CTNNB1
12 11.95 APC BCL2L1 BIRC5 CASP3 CTNNB1 HGF
13 11.94 CASP3 CTNNB1 GPC3 HGF IGF2 MET
14 11.92 AFP APC HGF MET
15
Show member pathways
11.74 CTNNB1 HGF MET
16
Show member pathways
11.69 BCL2L1 BIRC5 CASP3
17 11.62 BCL2L1 BIRC5 CASP3
18 11.4 APC CTNNB1 HNF1A
19 11.36 AFP APOA1 HNF1A
20 11.33 BCL2L1 BIRC5 CASP3 HNF1A
21 11.29 CTNNB1 HGF MET
22 10.97 ABCB1 BCL2L1 CASP3
23 10.73 APC CTNNB1 HGF MET
24 10.68 ABCB1 BCL2L1

GO Terms for Hepatoblastoma

Cellular components related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 beta-catenin destruction complex GO:0030877 9.16 APC CTNNB1
2 catenin complex GO:0016342 8.96 APC CTNNB1
3 Wnt signalosome GO:1990909 8.62 APC CTNNB1

Biological processes related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.72 BCL2L1 BIRC5 CTNNB1 HGF IGF2
2 negative regulation of inflammatory response GO:0050728 9.54 APOA1 HGF PPARA
3 fatty acid transport GO:0015908 9.4 HNF1A PPARA
4 hepatocyte growth factor receptor signaling pathway GO:0048012 9.26 HGF MET
5 cellular protein metabolic process GO:0044267 9.26 AFP APOA1 GPC3 IGF2
6 entry of bacterium into host cell GO:0035635 9.16 CTNNB1 MET
7 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 8.62 HGF MET

Molecular functions related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CASP3 CDKN1C

Sources for Hepatoblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....